| Publication number |
CLPUB00097 |
|---|
| Authors |
Stocker J.W., Forster H.K., Miggiano V., Stahli C., Staiger G., Takacs B., Stachein T. |
|---|
| Title |
Generation of two new myeloma cell lines 'PAI' and 'PAI-O' for hybridoma production. |
|---|
| Citation |
Res. Discl. 217:155-157(1982) |
|---|
| Abstract |
The development of the hybridoma technology (1) has allowed the production
of specific monoclonal antibodies which provide unique and invaluable
reagents for a variety of applications. The reliable production of
hybridoma cell lines is dependent on the availability of a suitable
myeloma cell line to act as a fusion partner for antibody-forming cells
While several cell lines exist for this purpose, none has in experiments
in our laboratory fulfilled all of the criteria for an ideal fusion
partner. These would include: 1) Rapid growth rate. 2) Growth in cheaper
tissue culture media (eg media supple-mented with horse serum rather than
the expensive fetal calf serum). 3) The line and its hybridoma descendents
should be readily clonable In soft agar or by dilution. 4) No production
of immunoglobulin (Ig) chains by the line. 5) High frequency of fusion
with antibody-forming cells. This assumes freedom from mycoplasma
contamination. 6) All stages in the generation and cloning of hybridomas
should be independent of feeder cells. 7) Hybridomas should be stable
producers of the monoclonal antibody. 8) Hybridoma cells should not die
under crowded conditions of culture (eg neglect over a weekend!).
This report describes the production of a line which has all these
characteristics using as the starting point the line P3-Ag8-gamma1- an Ig-
non-secretor clone of P3-X63-Ag8. The line P3-Ag8-gamma1- produces
intracellular kappa light chains (kappa) which are expressed in derived
hybridomas, resulting in 'scrambled' antibodies.
|
|---|
| Cell lines |
CVCL_J288; PAI CVCL_Z070; PAI-0 |
|---|
